About GemPharmatech
GemPharmatech is a company based in Nanjing (China) founded in 2018. GemPharmatech has raised $81.85 million across 2 funding rounds from investors including Morgan Stanley, Sinopharm Group and Hillhouse. The company has 10 employees as of December 31, 2022. GemPharmatech operates in a competitive market with competitors including Biocytogen, Applied StemCell, Interius Biotherapeutics, Nagi Bioscience and Business Catalyst, among others.
- Headquarter Nanjing, China
- Employees 10 as on 31 Dec, 2022
- Stage Public
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Gempharmatech Co., Ltd. Class A
-
Annual Revenue
$113.3 M (USD)16.15as on Dec 31, 2025
-
Net Profit
$20.63 M (USD)31.49as on Dec 31, 2025
-
EBITDA
Not available
-
Total Equity Funding
$81.85 M (USD)
in 2 rounds
-
Latest Funding Round
$58.49 M (USD), Series B
Sep 11, 2020
-
Investors
Morgan Stanley
& 6 more
-
Employee Count
10
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of GemPharmatech
GemPharmatech is a publicly listed company on the SSE with ticker symbol 688046 in China, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of GemPharmatech
Unlock access to complete
Unlock access to complete
Funding Insights of GemPharmatech
GemPharmatech has successfully raised a total of $81.85M across 2 strategic funding rounds. The most recent funding activity was a Series B round of $58.49 million completed in September 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in GemPharmatech
GemPharmatech has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Morgan Stanley, Sinopharm Group and Hillhouse.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Global private equity investments are managed with long-term focus.
|
Locked | Locked | Locked | |
|
Private equity investments are managed by Yunfeng Capital in China.
|
Locked | Locked | Locked | |
|
TF Capital is engaged in biotech investment and strategic support.
|
Locked | Locked | Locked |
Investor details for GemPharmatech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by GemPharmatech
Investment portfolio details for GemPharmatech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - GemPharmatech
Detailed financials for GemPharmatech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Gempharmatech Comparisons
Peer comparison for GemPharmatech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of GemPharmatech
GemPharmatech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biocytogen, Applied StemCell, Interius Biotherapeutics, Nagi Bioscience and Business Catalyst, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Integrated solutions for next-generation antibody drug development are provided.
|
|
| Locked | Locked | Locked |
Provider of animal and cell line models as tools for drug discovery and diagnostics
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating multiple diseases
|
|
| Locked | Locked | Locked |
Developer of a organism on a chip based technology
|
|
| Locked | Locked | Locked |
In-vivo mouse models are developed for biomedical R&D applications.
|
Detailed competitors of GemPharmatech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Gempharmatech
Complete news archive for GemPharmatech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about GemPharmatech
GemPharmatech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
GemPharmatech is headquartered in Nanjing, China. It is registered at Nanjing, Jiangsu, China.
GemPharmatech is a funded company, having raised a total of $81.85M across 2 funding rounds to date.
As of Dec 31, 2022, the latest employee count at GemPharmatech is 10.
Annual revenue of GemPharmatech is $113.3M as on Dec 31, 2025.
GemPharmatech was founded in 2018 and is located in Nanjing, China. Operations focus on the biotechnology sector, where humanized animal models are developed for drug and disease metabolism studies. Services include functional analysis, evaluation of transgenic mice, ES gene editing, and other model types. Additional technical support encompasses cell-line services and biological sample refrigeration, aiding research applications in pharmacology and related fields.
GemPharmatech's top competitors include Biocytogen, Applied StemCell and Interius Biotherapeutics.
Yes, GemPharmatech is publicly traded on SSE under the ticker symbol 688046.
GemPharmatech has 7 investors. Key investors include Morgan Stanley, Sinopharm Group, Hillhouse, Yunfeng Capital, and Sequoia Capital.
The ticker symbol of GemPharmatech is 688046 on SSE.